Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422205 | 1.00 | MAOB (0.55) | MAOBMAOASCN9AGRM5PARP10 | |
| SCHEMBL4422210 | 1.00 | MAOB (0.55) | MAOBMAOASCN9AGRM5PARP10 | |
| SCHEMBL4423323 | 0.88 | MAOB (0.45) | MAOBMAOASCN9APARP10 | |
| SCHEMBL4423318 | 0.88 | MAOB (0.45) | MAOBMAOASCN9APARP10 | |
| SCHEMBL4422233 | 0.86 | MRGPRX4 (0.49) | MAOBMAOASCN9AGRM5PARP10 | |
| SCHEMBL4422239 | 0.86 | MRGPRX4 (0.49) | MAOBMAOASCN9AGRM5PARP10 | |
| SCHEMBL3504638 | 0.82 | MRGPRX4 (0.52) | MAOBMRGPRX4 | |
| SCHEMBL3506459 | 0.82 | MRGPRX4 (0.52) | MAOBMRGPRX4 | |
| SCHEMBL5811161 | 0.82 | MAOB (0.49) | MAOBMAOASCN9AGRM5PARP10 | |
| SCHEMBL3504640 | 0.82 | MRGPRX4 (0.52) | MAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515926-B1 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-6951884-B2 | Fluorobenzamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | claimed |
| EP-1515926-A2 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | F.HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | claimed |
| US-20030236304-A1 | Fluorobenzamides and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-25 | — | — | US | claimed |
| WO-2003106380-A2 | FLUOROBENZAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | claimed |
| EP-1515926-B1 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-6951884-B2 | Fluorobenzamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1515926-A2 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | F.HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20030236304-A1 | Fluorobenzamides and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-25 | — | — | US | disclosed |
| WO-2003106380-A2 | FLUOROBENZAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236304-A1 | Fluorobenzamides and uses thereof | MAOB, MAOA, BCHE | MAOB 1/4885MAOA 2/4885SCN9A 2833/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885MAOA 2/4885SCN9A 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.